| Literature DB >> 36119311 |
Mukesh S Bawa1, Atul V Desale1, Harshal T Pandve1, Abhijit V Nimbalkar1, Tushar V Patil2, Laxman P Gophane3, Abhaychandra A Dadewar3, Pandurang Thatkar3, Shivaji T Dhage3, Medha K Kharat3, Shailaja M Bhavsar3, Rajendra P Firke3, Vijaya A Ambedkar3, Sunita S Salve3, Trupti M Sagale3.
Abstract
Context: Population-based seroepidemiological studies are recommended to measure the extent of spread of coronavirus disease of 2019 (COVID-19) infection in an area. The present seroprevalence survey was planned with the aim to estimate the cumulative burden of the COVID-19 disease in the Pimpri Chinchwad corporation area. Aims: To estimate the cumulative burden of the COVID-19 disease in the Pimpri Chinchwad corporation area. Settings and Design: The study was carried out in Pimpri Chinchwad Municipal Corporation (PCMC) city area. It was a descriptive cross-sectional survey. Materials andEntities:
Keywords: IgG; India; Pimpri Chinchwad; SARS-CoV-2; seroprevalence
Year: 2022 PMID: 36119311 PMCID: PMC9480686 DOI: 10.4103/jfmpc.jfmpc_1869_21
Source DB: PubMed Journal: J Family Med Prim Care ISSN: 2249-4863
Overall seroprevalence in PCMC
| SARS-CoV-2 IgG antibody | Blood samples | Percentage |
|---|---|---|
| Positive | 8207 | 81.34 |
| Negative | 1875 | 18.66 |
| Total | 10082 | 100 |
Association between IgG antibody status and study variables
| Variable | IgG antibody status | Chi-square | df |
| |||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Positive ( | Negative ( | Total ( | |||||||
|
|
|
| |||||||
|
| % |
| % |
| % | ||||
| Area of residence | |||||||||
| Slum | 1208 | 82.51 | 256 | 17.49 | 1464 | 14.52 | 23.7 | 2 | <0.001 |
| Tenements | 1959 | 84.48 | 360 | 15.52 | 2319 | 23.00 | |||
| Elite | 5040 | 80.01 | 1259 | 19.99 | 6299 | 62.48 | |||
| Age group (Years) | |||||||||
| 6-18 | 1150 | 70.6 | 480 | 29.4 | 1630 | 16.2 | 340 | 3 | <0.001 |
| 19-44 | 4125 | 78.9 | 1101 | 21.1 | 5226 | 51.8 | |||
| 45-60 | 1811 | 91.1 | 176 | 8.9 | 1987 | 19.7 | |||
| >60 | 1121 | 90.5 | 118 | 9.5 | 1239 | 12.3 | |||
| History of symptoms | |||||||||
| Asymptomatic | 6958 | 79.3 | 1812 | 20.7 | 8770 | 87 | 190 | 1 | <.001 |
| Symptomatic | 1249 | 95.2 | 63 | 4.8 | 1312 | 13 | |||
Figure 1Seropositivity among confirmed COVID-19 cases in past
Summary statistics
| Statistical variable | Numbers & percentage |
|---|---|
| Total population of PCMC | 2497085 |
| Detected COVID-19 cases (PCMC) as on 7 July 2021 | 258796 |
| Estimated COVID-19 cases (81.34% seropositivity) | 2031129 |
| Estimated asymptomatic seropositive (84.78%) | 1721991 |
| Estimated symptomatic seropositive (15.22%) | 308935 |
| Asymptomatic to symptomatic seropositive ratio | 5.57 |
| Deaths (PCMC) as on 7 July 2021 | 4301 |
| Seropositivity in PCMC | 81.34% |
| IFR | 0.21% |
| Case fatality rate | 1.67% |